"Inappropriate Use of Prasugrel post PCI" by Ahmed Amro, Kanaan Mansoor et al.

Article Title

Prasugrel Inappropriate Use in Patients Post-percutaneous coronary intervention (PCI). A Single Center Study

Authors

Author Credentials

Ahmed Amro MD Kanaan Mansoor MD Mohammad Amro MD Amal Sobeih MD Obadah Aqtash MD Hisham Hirzallah MD Alaa Gabi MD Madhulika Urella MD Waseem Ahmed MD Sandra Shenouda MD Rameez Sayyed MD

DOI

10.33470/2379-9536.1220

Abstract

Prasugrel is a thienopyridine that was approved by the US Food and Drug Administration (FDA) in combination with aspirin for the reduction of thrombotic events as well as stent thrombosis in patients with ACS who undergo PCI. This retrospective study aims to assess the frequency of inappropriate use of prasugrel and to emphasize that prasugrel still needs more attention as inappropriate use may result in significant morbidity.

Conflict(s) of Interest

The authors have no financial disclosures to declare and no conflicts of interest to report.

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 License.

Recommended Citation

Amro, Ahmed; Mansoor, Kanaan; Amro, Mohammad; Sobeih, Amal; Aqtash, Obadah; Hirzallah, Hisham; Gabi, Alaa; Urella, Madhulika; Ahmed, Waseem; Shenouda, Sandra; and Sayyed, MD, Dr. Rameez (2019) "Prasugrel Inappropriate Use in Patients Post-percutaneous coronary intervention (PCI). A Single Center Study," Marshall Journal of Medicine: Vol. 5: Iss. 3, Article 8.
DOI: 10.33470/2379-9536.1220
Available at: https://mds.marshall.edu/mjm/vol5/iss3/8

Download

Included in

Cardiology Commons, Critical Care Commons

COinS